Hepalink released its 2026 interim report. Total operating revenue was 2.58 billion yuan, down 8.44% from the same period last year. Net profit attributable to the parent company was 275 million yuan, down 34.74% year on year. Net cash inflow from operating activities was 815 million yuan, down 22.34% year on year. The company's asset-liability ratio was 26.52%, gross margin was 34.20%, return on equity was 2.31%, and diluted earnings per share was 0.19 yuan. The number of shareholders was 24,000, and the top ten shareholders held 85.91% of the total share capital.
Shenzhen Hepalink Pharmaceutical Co LtdNet profit fell 34.74% year on year, with revenue down 8.44%.
